The global Metabolomics Biomarker is growing at a significant rate owing to various factors such as ongoing research on metabolomics biomarker, innovative development in informatics and analytical technologies, and extensive applications such as in the detection of colorectal cancer. The increasing prevalence of colorectal cancer across the globe is one of the major factors for the wide adoption of metabolomics biomarkers for early detection of disease. According to the American Cancer Society, in 2019, the number of new colon cancer cases is estimated to be around 101,420 and the number of new rectal cancer is estimated to be nearly 44,180 in the US. The metabolomics is increasingly being adopted in the development of precision medicines for various chronic diseases such as cancer and CVD. This, in turn, is driving the growth of the global Metabolomics Biomarker market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/metabolomics-biomarker-market
Global Metabolomics Biomarker market has been segmented on the basis of technology, application, end-user, and regions. On the basis of technology, the market has been segregated into chromatography, mass spectrometry, nuclear magnetic resonance (NMR), and others. The chromatography segment is further sub-segmented into gas chromatography (GC), high-performance liquid chromatography (HPLC), and ultra-performance liquid chromatography (UPLC). Mass-spectrometry combined with chromatography technology is dominating the market share with around 65% contribution to the overall market in 2017. Mass spectrometry along with chromatography analyzes a wide range of metabolites of varying molecular weight; thereby, finds greater adoption across various end-user. Moreover, the combination has a high peak capacity to cover a wide range of concentrations and detect both hydrophobic and hydrophilic compounds, which supports their adoption in metabolomics in the various end-use application.
The key players operating in the global Metabolomics Biomarker market include BG Medicine, Inc., Biomark Diagnostics Inc., Evotec A.G., Merck KGaA, Metabolomic Diagnostics Ltd., Stemina Biomarker Discovery, Inc., and Thermo Fisher Scientific, Inc., among others. The companies are developing innovative Metabolomics Biomarker in the market, in order to develop effective diagnostic and treatment for infectious and metabolic diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the highly competitive market, which includes merger & acquisition, geographical expansion, joint ventures, and product development, among others.
Browse the full report description of "Metabolomics Biomarker Market at https://www.omrglobal.com/industry-reports/metabolomics-biomarker-market
Global Metabolomics Biomarker Market - Segmentation
By Application
• Toxicological Studies
• Drug Testing
• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Inborn Errors of Metabolism
• Other
By Technologies
• Gas Chromatography (GC)
• High-Performance Liquid Chromatography (HPLC)
• Ultra-Performance Liquid Chromatography (UPLC)
• Nuclear Magnetic Resonance (NMR)
• Mass Spectrometry
• Surface-Based Mass Analysis
• Bioinformatics
• Other
By End Users
• Hospitals
• Diagnostic Labs
• Research Centres
Global Metabolomics Biomarker Market – Segment by Region
North America
• US
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
About Us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-040